Company Overview: Synaptogenix (SNPX) - Possible New Alzheimer's Treatment

Synaptogenix (SNPX) is a clinical-stage biotechnology company that focuses on treating neurodegenerative diseases. Daniel Alkon, President and Chief Scientific Officer of Synaptogenix, discusses the development of a drug candidate called Bryostatin for the treatment of Alzheimer’s disease. He says that 94% of the patients who took the drug showed improvement in their cognitive function. He also talks about other restorative therapeutics Synaptogenix has in development as well as what’s next for the company.

The Watch List

25 Jun 2021

ON AIR
7:00 am
Market Overtime
replay

Get Market Minute

Daily insights for every investor

FOLLOW US

Company Overview: Synaptogenix (SNPX) - Possible New Alzheimer's Treatment

Synaptogenix (SNPX) is a clinical-stage biotechnology company that focuses on treating neurodegenerative diseases. Daniel Alkon, President and Chief Scientific Officer of Synaptogenix, discusses the development of a drug candidate called Bryostatin for the treatment of Alzheimer’s disease. He says that 94% of the patients who took the drug showed improvement in their cognitive function. He also talks about other restorative therapeutics Synaptogenix has in development as well as what’s next for the company.

The Watch List

25 Jun 2021

ON AIR
7:00 am
Market Overtime
replay

Get Market Minute

Daily insights for every investor

FOLLOW US